Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 as Neoadjuvant for PDT in BCC
NCT03467789Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vitamin d in basal cell carcinoma (BCC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Rate of tumor clearance at 6 months. Started Oct 2018; status: completed.
02
Drugs
vitamin d
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03467789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467789.